TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Zacks Investment Research • Aug 11, 2026

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restructuring and transaction costs) Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment 2 Quarter-end cash balance of $388 million and no debt DUBLIN, Aug. 10, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2026. "During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma.

PRNewsWire • Aug 10, 2026

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.

Seeking Alpha • Jul 1, 2026

Theravance Stock Down 3% After Zymeworks Announces Buyout

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.

Zacks Investment Research • Jun 30, 2026

Zymeworks strikes $929 million deal for Theravance Biopharma

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​deal.

Reuters • Jun 29, 2026

Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline

Theravance Biopharma strikes a deal with Zymeworks to be acquired for $17 a share.

Barrons • Jun 29, 2026

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other monetization of ampreloxetine within the next ten years Transaction follows a comprehensive strategic alternatives review conducted by the Company's Strategic Review Committee and Board of Directors Transaction expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions DUBLIN, June 29, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (Nasdaq: TBPH) today announced that it has entered into a definitive agreement pursuant to which Zymeworks Inc. will acquire the Company for $17.00 per share in cash, representing an equity value of approximately $929 million. In addition to the cash consideration, Theravance Biopharma shareholders will receive a CVR entitling them to 80% of net proceeds realized from any future license, divestiture or other monetization of ampreloxetine over the next ten years, with the remaining 20% to Zymeworks.

PRNewsWire • Jun 29, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

NEW YORK, June 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Theravance Biopharma, Inc. (NASDAQ: TBPH ) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00 per share in cash and (ii) one contingent value right.

PRNewsWire • Jun 29, 2026

Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jun 29, 2026

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Theravance and its board of directors violat.

Business Wire • Jun 29, 2026